Maze Therapeutics MAZE 深 滬
已收盤 11-06 16:00:00 美东时间
34.19
+1.660
+5.10%
華盛通- 最 高35.00
- 今 開32.72
- 成交量 56.39万股
- 最 低 32.4208
- 昨 收 32.53
- 總市值 18.99亿
- 52周最高 53.65
- 市盈率 靜 --
- 換手率 1.02%
- 52周最低 21.95
- 委 比 84.76%
- 總股本 5554.92万
- 歷史最高 53.65
- 量 比 1.21
- 振 幅 7.93%
- 歷史最低 6.71
- 每 手 1
- 風險率 8.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Maze Therapeutics收涨3.5%，成交额1777.14万美元
11月5日，Maze Therapeutics（MAZE）收涨3.5%，报33.38美元，成交额1777.14万美元，市值18.5亿美元。 行情数据 • 开盘价...
11-05 06:29
Maze Therapeutics to Participate in Upcoming Investor Conferences
Maze Therapeutics, Inc. announced that its CEO, Jason Coloma, Ph.D., will participate in three investor conferences in November and December 2026. The events include the Guggenheim Healthcare Innovation Conference on November 10, the Jefferies Global Healthcare Conference in London on November 17, and the Evercore Healthcare Conference on December 1. Live webcasts will be available on the company's website and archived for 60 days. Maze Therapeut...
11-03 12:00
Maze Therapeutics收涨0.13%，成交额1237.52万美元
10月29日，Maze Therapeutics（MAZE）收涨0.13%，报31.73美元，成交额1237.52万美元，市值17.63亿美元。 行情数据 •...
10-29 05:30
Maze Therapeutics收涨0.19%，成交额1339.52万美元
10月27日，Maze Therapeutics（MAZE）收涨0.19%，报31.07美元，成交额1339.52万美元，市值17.26亿美元。 行情数据 •...
10-27 05:31
美股大行评级 | 潜在涨幅523.44%！HC Wainwright & Co.上调Annexon目标价至25美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Annexon"买入"评级，目标价从14美元升至25美元；HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从55美元升至60美元
10-20 12:36
Canaccord Genuity Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $75
Canaccord Genuity analyst Whitney Ijem initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Target of $75.
10-19 20:16
Maze Therapeutics收涨0.18%，成交额2799.68万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:36
Maze Therapeutics adjusts equity via warrant exchange
Maze Therapeutics, Inc. ( ($MAZE) ) has shared an announcement. On October 15, ...
10-17 04:34
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Maze Therapeutics will present data on its lead programs, MZE829 and MZE782, at the American Society of Nephrology (ASN) Kidney Week 2026. The company will deliver an oral presentation on Phase 2 HORIZON trial results for MZE829 in APOL1-mediated kidney disease (AMKD) and two posters on preclinical research supporting SLC6A19 inhibition for chronic kidney disease (CKD). CEO Jason Coloma emphasized the importance of these presentations in advancin...
10-06 20:05
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
